Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Debra Birnkrant
Benefit-Risk Assessment for Sofosbuvir/Velpatasvir/Voxilaprevir Based on Patient Population and HCV Genotype: FDA's Evaluation
Hepatology
Medicine
Hepatology
Related publications
Sofosbuvir and Velpatasvir: A Complete Pan-Genotypic Treatment for HCV Patients
Turkish Journal of Gastroenterology
Gastroenterology
Sofosbuvir-Velpatasvir-Voxilaprevir With or Without Ribavirin in Direct-Acting Antiviral-Experienced Patients With Genotype 1 Hepatitis C Virus
Hepatology
Medicine
Hepatology
Sofosbuvir, Peg Interferon & Ribavirin for Retreatment of HCV Genotype 1b Following Sofosbuvir and Ledipasvir Failure
Hepatology
Medicine
Hepatology
Development and Validation of Rp-HPLC Method for the Simultaneous Estimation of Sofosbuvir, Velpatasvir and Voxilaprevir in Bulk and Tablet Dosage Forms
Rasayan Journal of Chemistry
Pharmacology
Biochemistry
Energy
Chemical Engineering
Toxicology
Chemistry
Pharmaceutics
Sofosbuvir and Velpatasvir With or Without Voxilaprevir in Direct-Acting Antiviral-Naïve Chronic Hepatitis C: Patient-Reported Outcomes From POLARIS 2 and 3
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Benefit–risk Assessment of New and Emerging Treatments for Hepatitis C: Focus on Simeprevir and Sofosbuvir
Drug, Healthcare and Patient Safety
Health Policy
Pharmacology
Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial
Hepatology
Medicine
Hepatology
High Efficacy of Sofosbuvir/Velpatasvir and Impact of Baseline Resistance-Associated Substitutions in Hepatitis C Genotype 3 Infection
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Sofosbuvir/Velpatasvir for Chronic Hepatitis C Infection in Patients With Transfusion-Dependent Thalassemia
American Journal of Hematology
Hematology
